Arcadia Consumer Healthcare acquires Kaopectate from SanofiChristian Fernsby ▼ | March 21, 2020
Arcadia Consumer Healthcare, formerly Kramer Laboratories, a recognized leader in the consumer healthcare industry, yesterday announced that is has completed the acquisition of the U.S. rights to the Kaopectate brand from Sanofi.
Acquisition Arcadia Consumer Healthcare
Topics: Arcadia Consumer Healthcare acquire Kaopectate Sanofi
With its demonstrated ability to turn around brands and drive category leading growth through investment and innovation, Arcadia also has an eye towards additional strategic acquisitions.
Kaopectate® has been a leader in the treatment of diarrhea and upset stomach for more than 75 years and has been trusted by millions of Americans during that time.
Available in both liquid and caplets, Kaopecate provides safe and effective relief and is available at all major retailers throughout the U.S. ■